Want to see SE:QCORE full AI Analyst Report?
QCORE Stock Chart & Stats
kr0.50
-kr0.12(-3.11%)
At close: 4:00 PM EST
kr0.50
-kr0.12(-3.11%)
Day’s Range― - ―
52-Week Rangekr0.21 - kr1.70
Previous CloseN/A
Volume1.64K
Average Volume (3M)106.36K
Market Cap
kr16.30M
Enterprise Valuekr18.38
Total Cash (Recent Filing)kr2.97M
Total Debt (Recent Filing)kr1.40M
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Sep 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding42,900,500
10 Day Avg. Volume135,027
30 Day Avg. Volume106,359
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.38
Price to Sales (P/S)2.07
P/FCF Ratio-1.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt relative to equity reduces bankruptcy and refinancing risk over time, giving management flexibility to weather continued operating losses or to raise growth capital on less onerous terms. This structural strength supports survival while pursuing product or go-to-market adjustments.
Recurring License/subscription RevenueA subscription/license model provides a base of repeatable revenue and potential for predictable renewals. Over months this supports revenue visibility, higher lifetime value if retention improves, and scalability because incremental sales often have low marginal costs relative to initial customer acquisition.
Niche In Genomics And Precision MedicineSpecialization in high-dimensional omics analysis targets a growing, structural market (genomics, precision medicine). Deeply embedded research workflows and data integration create stickiness, enabling long-term commercial opportunities with academic, clinical, and pharma customers as demand for omics analytics expands.
Bears Say
Persistent Losses And Revenue ContractionSustained net losses and shrinking revenue erode the firm's equity base and constrain reinvestment in product and sales. Over a multi-month horizon this pattern makes it harder to achieve scale, increases reliance on external funding, and raises execution risk for any turnaround strategy.
Consistent Negative Operating And Free Cash FlowMulti-year cash outflows indicate the business is not self-funding. Persistent cash burn forces dependence on financing or dilution, limits ability to invest in R&D or commercialization, and creates vulnerability to funding market conditions over the coming months.
Deteriorating Margins / Gross Profit Swing NegativeA swing to negative gross profit signals structural margin problems (higher direct costs or pricing pressure) uncommon for software. This undermines the economics of scaling and suggests profitability will be difficult to restore without meaningful cost restructuring or a change in revenue mix.
QCORE FAQ
What was Qlucore AB’s price range in the past 12 months?
Qlucore AB lowest stock price was kr0.21 and its highest was kr1.70 in the past 12 months.
What is Qlucore AB’s market cap?
Qlucore AB’s market cap is kr16.30M.
When is Qlucore AB’s upcoming earnings report date?
Qlucore AB’s upcoming earnings report date is Sep 09, 2026 which is in 45 days.
How were Qlucore AB’s earnings last quarter?
Qlucore AB released its earnings results on May 28, 2026. The company reported -kr0.079 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Qlucore AB overvalued?
According to Wall Street analysts Qlucore AB’s price is currently Overvalued.
Does Qlucore AB pay dividends?
Qlucore AB does not currently pay dividends.
What is Qlucore AB’s EPS estimate?
Qlucore AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Qlucore AB have?
Qlucore AB has 42,900,500 shares outstanding.
What happened to Qlucore AB’s price movement after its last earnings report?
Qlucore AB reported an EPS of -kr0.079 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.708%.
Which hedge fund is a major shareholder of Qlucore AB?
Currently, no hedge funds are holding shares in SE:QCORE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Qlucore AB
Based in Lund, Sweden, Qlucore AB (publ) delivers advanced bioinformatics data analysis tools for global application in both scientific research and accurate medical diagnostics. Its product suite includes Qlucore Omics Explorer, an AI-powered bioinformatics software designed for research across various sectors such as life science, biotechnology, food, plant industries, and academia. Additionally, the company offers Qlucore Diagnostics, a specialized software platform for multi-omics companion and precision diagnostics, as well as Qlucore Insights, which facilitates the analysis of clinical data. Qlucore was established in 2007.
Technical Analysis
Divio Technologies AB Class B
―
Flowscape Technology AB
―
Safeture AB
―
Generic Sweden AB
―
―